Study of PAT in Patients With Solid Tumor Cancers

This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor

NCT Number	NCT05338658
Lead Sponsor	Masonic Cancer Center, University of Minnesota
Conditions	Metastasis, Solid Tumor
Enrollment	21 participants
Start Date	2023-05-19
Primary Completion	2027-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-09